Background: Florbetapir F 18 ( 18 F-AV-45) is a positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease. Earlier data showed that florbetapir F 18 binds with high affinity to b-amyloid (Ab) plaques in human brain homogenates (Kd=3.7 nM) and has favorable imaging pharmacokinetic properties, including rapid brain penetration and washout. This study used human autopsy brain tissue to evaluate the correlation between in vitro florbetapir F 18 binding and Ab density measured by established neuropathologic methods.
Methods: The localization and density of florbetapir F 18 binding in frozen and formalin-fixed paraffin-embedded sections of postmortem brain tissue from 40 patients with a varying degree of neurodegenerative pathology was assessed by standard florbetapir F 18 autoradiography and correlated with the localization and density of Ab identified by silver staining, thioflavin S staining, and immunohistochemistry.
Results: There were strong quantitative correlations between florbetapir F 18 tissue binding and both Ab plaques identified by light microscopy (Silver staining and thioflavin S fluorescence) and by immunohistochemical measurements of Ab using 3 antibodies recognizing different epitopes of the Ab peptide. Florbetapir F 18 did not bind to neurofibrillary tangles.
Conclusions: Florbetapir F 18 selectively binds Ab in human brain tissue. The binding intensity was quantitatively correlated with the density of Ab plaques identified by standard neuropathologic techniques and correlated with the density of Ab measured by immunohistochemistry. As Ab plaques are a defining neuropathologic feature for Alzheimer disease, these results support the use of florbetapir F 18 as an amyloid positron emission tomography ligand to identify the presence of Alzheimer disease pathology in patients with signs and symptoms of progressive late-life cognitive impairment.
Key Words: PET imaging, Alzheimer disease, Ab plaque, autoradiography, Ab, amyloid PET imaging, florbetapir F 18, 18 F-AV-45, postmortem (Alzheimer Dis Assoc Disord 2012; 26:8-16) A lzheimer disease (AD) pathology is thought to begin years before the first clinical manifestations of brain failure. The inability to directly identify the pathologic changes in living persons and the overlap of signs and symptoms associated with different late-life neurodegenerative dementing diseases adds a measure of uncertainty to the clinical diagnosis of AD in individual patients. The inclusion of pathologically linked biomarkers in the clinical evaluation of patients with progressive late-life cognitive impairment should improve clinical diagnostic accuracy. 1, 2 The presence of Ab plaques is a defining neuropathologic feature of AD. 3 Several radioactively labeled molecules have been identified as potentially useful PET ligands to visualize Ab aggregates. The most widely studied ligand is 11 Clabeled Pittsburgh compound B ( 11 C-PiB), a thioflavin T derivative. Preclinical and clinical studies suggest that 11 C-PiB binds with high affinity and selectivity to amyloid aggregates in the brain. [7] [8] [9] However, the 20-minute half-life of 11 C limits its use in routine clinical care and has triggered the search for 18 F-ligands. Three 18 F-ligands are currently in active development: florbetapir F 18 ( 18 F-AV-45, Avid), florbetaben F 18 (BAY 94-9172, Bayer-Schering), 10 and flutemetamol F 18 (GE067, General Electric). 11 Early data showed that florbetapir F 18 binds with high affinity to Ab plaques in human brain homogenates (Kd=3.7 nM) and has desirable brain imaging pharmacokinetic properties, including rapid brain penetration and washout. [12] [13] [14] Initial in vitro autoradiography (ARG) studies showed that florbetapir F 18 bound with high affinity to Ab deposits in tissue sections from brains of patients with AD, whereas no signal was observed in tissue sections from controls. 12 The objectives of the study were to validate the ability of florbetapir F 18 to accurately identify and quantify amyloid aggregates in human autopsy tissue by (1) determining the relationship between florbetapir F 18 tissue retention as measured by ARG and the localization of amyloid plaques using double-labeling studies, and (2) determining the correlation between the intensity of the ligand signal [amount of florbetapir F 18 required to saturate binding sites (Bmax) or ARG optical density] and Ab deposition using state-ofthe-art neuropathologic methods.
METHODS

Autoradiography
Florbetapir F 18 ARG was performed on sections of postmortem human brain tissue from 40 older patients with and without AD or other age-related pathologies. We included 24 cases from the Religious Orders Study of the Rush Alzheimer's Disease Center (Rush ADC) at Rush University, Chicago, IL, selected to ensure representation of a spectrum of AD pathology, 15 and 16 from the Banner Sun Health Research Institute Brain Donation Program (BSHRI), Sun City, AZ, 16 chosen to represent a range of pathologic diagnoses including 2 individuals free of pathology, 7 patients with AD, 3 patients with vascular dementia, and 4 patients with progressive supranuclear palsy.
Autopsy procedures from both studies have been described earlier. 15, 16 In brief, tissue from the frontal cortex was fixed in 4% paraformaldehyde, embedded in paraffin, and cut to prepare 6-mm sections (Rush ADC). In addition, frozen tissue was available from the 16 of the BSHRI cases. The florbetapir F 18 ARG and Ab binding (Bmax binding), and the double-labeling studies were carried out at Avid Radiopharmaceuticals.
In Vitro Florbetapir F 18 ARG and Double Labeling
Florbetapir F 18 was synthesized as described earlier 12 and incubated with the brain tissue sections. After drying, the sections were exposed to Kodak Biomax MR film for 12 to 18 hours. The images were digitized and the optical density of the signal in the gray matter was determined.
To evaluate the colocalization of florbetapir F 18 binding with neuritic plaques, double labeling of ARG and thioflavin S fluoromicroscopy was performed in sections from the same tissue blocks used for the silver and immunohistochemistry (IHC) staining.
After incubation with florbetapir F 18, the 6-mm sections were immersed in 10% neutral buffered formalin for 1 hour, treated with 0.05% KMnO 4 followed by 0.2% K 2 S 2 O 5 per 0.2% oxalic acid for quenching of autofluorescence, and stained with 0.025% thioflavin S. The density of fluorescencepositive neuritic plaques was evaluated visually under the microscope using a semiquantitative scoring of 0 (none), 1 (sparse), 2 (moderate), and 3 (frequent).
Semiquantitative Measures of Ab Plaques and Neurofibrillary Tangles
Neuritic and diffuse Ab plaques and neurofibrillary tangles from the 24 Rush ADC patients were identified on 6-mm sections using a modified Bielschowsky sliver stain. 17 The density of each of the 3 pathologies was determined by counting the number of each in a 1 mm 2 area (Â 100 magnification) in the region with greatest density for that particular measure, and then assigning a 6-level semiquantitative score of 0 (none) to 5 (frequent), based on these counts.
For the 16 BSHRI cases, a Campbell-Switzer silver stain was used to identify Ab plaques and a Gallyas silver stain to identify neurofibrillary tangles. A semiquantitative score ranging from 0 (none) to 3 (very dense) in quarterpoint increments was used to assess plaque and tangle density. All plaque types (ie, neuritic and diffuse) were included in the plaque score.
The neuropathologic assessment was carried out by experts blinded to the results of florbetapir F 18 ARG, thioflavin S staining, and Ab tissue binding (Bmax).
Quantitative Measures of Ab Aggregation by Image Analysis
The density of Ab was quantified using 3 different antibodies; 10D5, a monoclonal mouse anti-human Ab antibody, that recognizes the N-terminal of the Ab peptide 18 (courtesy of Elan Pharmaceuticals, South San Francisco, CA); 6F/3D, a monoclonal mouse anti-human Ab antibody, that recognizes an epitope near the N-terminus of the Ab peptide 19, 20 (Dako North America; Carpinteria, CA); and 4G8, a monoclonal anti-human Ab antibody that recognizes an epitope generated by amino acids 17 to 24 in the middle of the human Ab peptide 21, 22 (Covance, Princeton NJ). The IHC studies were carried out on sections adjacent to those used for silver staining and ARG.
For studies using 10D5 (dilution 1:300) and 6F/3D (dilution 1:50), tissue samples from the 24 Rush ADC patients were stained using an Automated Leica Bond Immunostainer (Leica Microsystems Inc., Bannockburn, IL). An investigator blinded to the clinical and pathologic data, outlined the cortical gray region of interest on each slide using a Microbrightfield Stereology System. The Stereo Investigator 8.0 software program (MicroBrightField, Inc., Williston, VT) was used to place a 1300Â1030 mm grid over the region and 200Â images were captured at interval grid intersection points. Area analysis was performed using Image J 1.42 g (http://rsbweb.nih.gov/ij/), which segmented each image along the intensity domain into 2 fractions, the labeled (amyloid) and the background compartment. The mean fraction of Ab per region and per patient was computed, yielding a value for the area occupied by amyloid. Data from 2 adjacent blocks of tissue (1 cm apart) were averaged to obtain a composite measure of the percentage of area occupied by Ab in each region of interest. 10D5 and 6F/3D IHC were carried out on adjacent sections from the same block.
The 4G8 antibody studies were performed using sections cut from 2 tissue blocks taken from the frontal lobe of 21 of 24 Rush ADC cases (tissue for IHC from both blocks was not available for 3 cases). Deparaffinized and rehydrated 6-mm thick tissue sections underwent formic acid-induced antigen retrieval, and were incubated with the anti-Ab antibody 4G8 (Covance; dilution 1:2000, 90 min) and subsequently visualized with anti-rabbit biotin-streptavidin horseradish peroxidase and 3-amino-9-ethylcarbazole chromogen. The sections were counterstained with Acid Blue 129 and coverslipped using an aqueous mounting media. 23 The stained slides were digitized using a Zeiss MIRAX high-resolution, automated slide scanner (Carl Zeiss Canada, Toronto, ON), and the digital images were converted from MIRAX to MINC (Medical NetCDF) file format. Image quantification was performed using the PERMITS image processing/analysis software (Biospective Inc., Montreal, Canada). This automated quantification method segments chromogen-positive pixels based on red-green-blue intensity and generates a parametric map of Ab burden over the entire tissue section. The amyloid burden (% area) was then calculated for the gray matter (ie, cortex) and white matter for each tissue section.
Florbetapir F 18 Binding in Tissue Homogenates
The methods used to evaluate the binding of florbetapir F 18 to brain tissue homogenates are described in detail elsewhere. 12 In brief, using frozen tissue from the 16 BSHRI cases, gray matter was homogenized and saturation binding assays carried out using BenzoThiazole-Aniline-1 (8 mM) to define nonspecific binding.
RESULTS
Colocalization of Florbetapir F 18 ARG and Amyloid Plaques
There was good colocalization of the florbetapir ARG signal with thioflavin S-positive neuritic plaque structures when tissue sections from formalin-fixed, paraffin-embedded tissue sections from patients with AD were double labeled with florbetapir F 18 (Fig. 1 ).
Correlation of Florbetapir F 18 Binding With Ab Plaques and Neurofibrillary Tangles
Florbetapir F 18 ARG showed a broad spectrum of signal intensities in the 16 BSHRI tissue samples. Representative ARG images are shown in Figure 2 . The density of florbetapir F 18 binding was quantified by optical measurements of the autoradiographic signal and compared with the Bmax in homogenates of tissue adjacent to the ARG sections (Table 1 ). There was a strong (r=0.95) correlation between the density of the autoradiographic signal and its Bmax to amyloid aggregates in the brain homogenates ( Table 2 ).
In addition, total plaques scores (BSHRI method) in these 16 cases correlated with both the Bmax of florbetapir F 18 binding in tissue homogenates (r=0.88) and the optical density of the ARG signal (r=0.95) ( Table 2 ). In contrast, neurofibrillary tangle scores were not significantly associated with florbetapir F 18 binding (r=0.33; P=0.21).
The relationship between florbetapir F 18 ARG binding and plaque score was explored further using postmortem brain tissue from the 24 Rush University cases. These samples also had various degrees of amyloid plaque pathology as determined by silver staining. As seen with the BSHRI cases, there were strong correlations between the florbetapir F 18 autoradiographic signal intensity and semiquantitative plaque density identified by both Bielschowsky silver and thioflavin S with Spearman rank correlation coefficient values of 0.71 and 0.81, respectively ( Table 3 ).
Correlation of Florbetapir F 18 Binding and Quantitative Measures of Ab Aggregation
We compared the IHC values (average of 2 areas from the frontal lobe of each patient) for each of the 3 amyloid antibodies with the florbetapir F 18 ARG average value from the same 2 areas. Figure 3 shows representative examples of immunohistochemical staining for each antibody. The correlation coefficients and P values comparing florbetapir F 18 ARG with Ab density measured by 6F/3D, 4G8, and 10D5, and by Bielschowsky silver staining and thioflavin S fluorescence are presented in Table 3 . Figure 4 shows the 4G8 Ab immunostaining and the florbetapir F 18 ARG of adjacent sections. A comparison of the IHC quantification and florbetapir F 18 autoradiographical density for each of the 21 tissue samples is shown in Table 4 . All 3 Ab antibodies correlated well with florbetapir F 18, yielding correlation coefficients between 0.75 and 0.88. There was also an excellent correlation among the 3 antibodies. These data are plotted ( Fig. 5 ).
DISCUSSION
The addition of pathologically linked biomarkers to the assessment of patients with progressive late-life cognitive impairment will likely improve the validity of a clinical diagnosis of AD made at the earliest symptomatic stage. These studies represent the first documentation of the correlation between a florbetapir F 18 ARG signal and the microscopic and IHC quantification of Ab, including plaque pathology, in human autopsy tissue. The data support the following conclusions: (1) there is a strong correlation between the density of in vitro florbetapir F 18 binding in human autopsy tissue semiquantitative estimates of Ab plaque density as determined by both silver and thioflavin S stains; (2) there is an equally strong correlation between the density of in vitro florbetapir F 18 binding and the density of Ab as determined by image analysis of immunostained brain sections using 3 different Ab antibodies; (3) the intensity of the florbetapir F 18 ARG signal in human autopsy sections is correlated with the degree of ligand binding in regional brain homogenates; and (4) florbetapir F 18 does not bind to neurofibrillary tangles in human postmortem tissue. Confidence in these findings is strengthened by the data obtained in the ARG-thioflavin S double-labeling study which provides direct evidence that florbetapir F 18 labels amyloid plaques identified by thioflavin S. Further support in the findings is gained by the equivalent quantitative results obtained from 3 different antibodies, each binding to a different epitope of the Ab peptide. Overall, these findings confirm that florbetapir F 18 is a direct and accurate marker of Ab in human autopsy tissue and supports its use as a reliable marker for Ab density in patients with signs and symptoms of late-life dementia.
To the best of our knowledge, this study provides the first rigorous correlation between the labeling intensity of an 18 and Ab deposition quantified with an immunohistochemical method using the 6E10 Ab antibody in a population of 14 human patients. In addition, they established a strong correlation between the binding of the fluorescent analog 6-CN-PiB and the Ab immunohistochemical signal in sections from 19 different cortical areas of a single patient with AD.
The findings of this postmortem study strongly supports the conclusion that the PET signals obtained in vivo with florbetapir F 18 provide a true reflection of the overall Ab aggregation in the human brain. Two small studies provide similar evidence for 11 C-PiB. Leinonen et al 27 C-PiB scans and abundant Ab immunoreactive deposits in their brain. One patient had a negative amyloid PET scan and the brain tissue was found to have only rare Ab plaques. A definitive conclusion that in vivo PET accurately reflects the Ab brain pathology will require a prospective study, comparing amyloid PET signal intensity with postmortem Ab plaque deposition.
This study compared florbetapir F 18 binding with estimates of total Ab load in the brain using diverse methodologies including silver and thioflavin S staining, Ab IHC, and Ab tissue homogenate binding. Ab aggregates of different physical structures and morphologies contribute to the total Ab tissue content. These include Ab contained in neuritic plaques, diffuse plaques, protofibrils, soluble oligomers, and less structured aggregates. [29] [30] [31] [32] [33] Although there is no precise and generally accepted definition of the various physical forms of amyloid, all may contribute to florbetapir F 18 binding. Lockhart et al 24 reported correlations between histochemically and autoradiographically demonstrated morphological forms of amyloid deposition (including diffuse plaques, neuritic plaques, cored plaques, and amyloid angiopathy). These investigators and Ikonomovic et al 26 also reported weak, but specific, binding of 11 C-PiB to neurofibrillary tangles. Owing to the weakness of the signal generated by tangle binding, the investigators suggested the tangle binding would not appreciably alter the overall signal when plaques are also present. This study with florbetapir F 18 shows that there is no significant correlation between estimates of neurofibrillary tangle density and florbetapir F 18 binding in tissue sections containing both plaques and tangles.
Florbetapir F 18 holds promise as a clinically informative diagnostic tool for the evaluation of individuals with signs and symptoms of late-life cognitive impairment. The demonstration of a strong, quantitative, and statistically highly significant correlation between postmortem binding of the ligand and Ab plaque deposition supports the conclusion that florbetapir F 18 binding is a reliable and quantitative marker of amyloid load in the human brain. As the presence of Ab plaques in the brain is a defining pathologic feature for AD, florbetapir F 18 PET imaging of patients with signs and symptoms of progressive late-life cognitive impairment should be an informative clinical tool for the identification of AD pathology.
